<- Go Home
Gilead Sciences, Inc.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.
Market Cap
$107.2B
Volume
6.7M
Cash and Equivalents
$2.8B
EBITDA
$13.5B
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$21.5B
Profit Margin
77.44%
52 Week High
$87.86
52 Week Low
$62.07
Dividend
3.58%
Price / Book Value
5.87
Price / Earnings
102.59
Price / Tangible Book Value
-8.34
Enterprise Value
$126.7B
Enterprise Value / EBITDA
9.30
Operating Income
$10.7B
Return on Equity
5.26%
Return on Assets
11.54
Cash and Short Term Investments
$3.8B
Debt
$23.4B
Equity
$18.2B
Revenue
$27.8B
Unlevered FCF
$7.4B
Sector
Biotechnology
Category
N/A